Sanctuary Advisors LLC Has $1.67 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sanctuary Advisors LLC raised its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 58.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,042 shares of the medical equipment provider’s stock after acquiring an additional 6,656 shares during the quarter. Sanctuary Advisors LLC’s holdings in Lantheus were worth $1,674,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the business. State of New Jersey Common Pension Fund D raised its holdings in shares of Lantheus by 0.4% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 26,428 shares of the medical equipment provider’s stock valued at $2,364,000 after purchasing an additional 115 shares in the last quarter. Rhumbline Advisers raised its holdings in Lantheus by 1.5% during the fourth quarter. Rhumbline Advisers now owns 212,673 shares of the medical equipment provider’s stock valued at $19,026,000 after buying an additional 3,136 shares in the last quarter. Van ECK Associates Corp raised its holdings in Lantheus by 31.7% during the fourth quarter. Van ECK Associates Corp now owns 76,996 shares of the medical equipment provider’s stock valued at $6,888,000 after buying an additional 18,524 shares in the last quarter. MeadowBrook Investment Advisors LLC boosted its stake in shares of Lantheus by 40.1% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 2,305 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 660 shares in the last quarter. Finally, JSF Financial LLC acquired a new position in shares of Lantheus during the 4th quarter valued at about $894,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 0.9 %

Shares of LNTH stock opened at $78.95 on Tuesday. The firm has a market capitalization of $5.49 billion, a P/E ratio of 13.14 and a beta of 0.44. Lantheus Holdings, Inc. has a 1 year low of $56.44 and a 1 year high of $126.89. The firm’s fifty day simple moving average is $90.02 and its 200 day simple moving average is $96.93.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LNTH. Truist Financial restated a “buy” rating and issued a $120.00 target price (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. The Goldman Sachs Group began coverage on shares of Lantheus in a research note on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. Finally, JMP Securities reissued a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Insiders Place Their Bets

In related news, Director James H. Thrall sold 1,000 shares of the stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total value of $94,760.00. Following the completion of the sale, the director now owns 33,207 shares in the company, valued at approximately $3,146,695.32. This trade represents a 2.92 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.